<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312831</url>
  </required_header>
  <id_info>
    <org_study_id>EMIS-112-C-02</org_study_id>
    <nct_id>NCT01312831</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin</brief_title>
  <official_title>A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emisphere Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emisphere Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety profile of a new oral vitamin
      B12 formulation (Eligen® B12) with intramuscular B12 in restoring normal B12 (cobalamin)
      concentrations in subjects with low cobalamin levels (&lt;350 pg/mL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Cobalamin Normalization</measure>
    <time_frame>61 days</time_frame>
    <description>The primary efficacy outcome compares the proportion of subjects in each treatment arm in whom cobalamin levels are normalized (i.e., cobalamin ≥ 350 ng/mL) following 60 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of B12 Normalization</measure>
    <time_frame>91 days</time_frame>
    <description>Maintenance of cobalamin normalization after 90 days of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Normalization</measure>
    <time_frame>90 days</time_frame>
    <description>Time to normalization of cobalamin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Cobalamin Levels After 60 and 90 days of Treatment</measure>
    <time_frame>91 days</time_frame>
    <description>Change from baseline is defined as (X-B) where B is the baseline (pre-dose Day 1) measurement of cobalamin (pg/mL) and X is the measurement of cobalamin(pg/mL) at Day 61 or Day 91, as required.
Percent change from baseline is defined as 100(X-B)/B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Methylmalonic Acid (MMA) Levels After 60 and 90 Days of Treatment</measure>
    <time_frame>91 days</time_frame>
    <description>Change from baseline is defined as (X-B) where B is the baseline (pre-dose Day 1) measurement of MMA (ng/mL) and X is the measurement of MMA (ng/mL) at Day 61 or Day 91, as required.
Percent change from baseline is defined as 100(X-B)/B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Homocysteine Levels After 60 and 90 Days of Treatment</measure>
    <time_frame>91 days</time_frame>
    <description>Change from baseline is defined as (X-B) where B is the baseline (pre-dose Day 1) measurement of homocysteine (umol/L) and X is the measurement of homocysteine (umol/L) at Day 61 or Day 91, as required.
Percent change from baseline is defined as 100(X-B)/B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>91 days</time_frame>
    <description>The safety and tolerability of Eligen® B12 and intramuscular B12 assessed by physical examination findings, clinical laboratory test results, vital signs, 12-lead ECG results and adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holo-trancobalamin (holo-TC) Normalization</measure>
    <time_frame>91 days</time_frame>
    <description>The proportion of subjects who achieve normalization of holo-TC levels (≥ 40 pmol/L) on Days 61 and 91 as an exploratory endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holo-TC and Cobalamin Correlation</measure>
    <time_frame>91 days</time_frame>
    <description>Holo-TC levels in relation to cobalamin levels on Days 61 and 91 as an exploratory endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Vitamin B 12 Deficiency</condition>
  <arm_group>
    <arm_group_label>Oral Eligen® B12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM B12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin B12 (cyanocobalamin)</intervention_name>
    <arm_group_label>Oral Eligen® B12</arm_group_label>
    <arm_group_label>IM B12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vitamin B12 deficiency defined as serum cobalamin below 350 pg/mL

          -  Age 60 or older; or age 18 or older with gastrointestinal abnormalities including but
             not limited to gastrointestinal surgery (e.g. gastrectomy, gastric bypass), ileal
             resection, gastric atrophy, Celiac disease, Crohn's disease, or prolonged use (&gt;3
             months) of proton pump inhibitor drugs, or on a restricted diet (such as vegetarian or
             vegan).

          -  General good health, as indicated by lack of significant findings in medical history,
             physical examination, clinical laboratory tests (chemistry, hematology and
             urinalysis), vital signs, ECG and normal kidney function as determined by estimated
             creatinine clearance computed with the Cockcroft and Gault formula

        Exclusion Criteria:

          -  Current treatment from a health care provider to treat vitamin B12 deficiency and/or
             symptoms;

          -  Daily use of neutralizing antacids (e.g. Maalox®)

          -  Inability to ingest oral medication

          -  Clinically significant laboratory value at screening

          -  Hypersensitivity or allergic reaction to vitamin B12

          -  Participation in a clinical research study involving a new chemical entity within 30
             days of the first study dose

          -  Folate levels below the reference range provided by the clinical laboratory.

          -  Renal insufficiency

          -  Vitamin B6 deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benno Roesch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frontage (formerly ABR), 241 Main Street, Hackensack, NJ 07601 USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Allegar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alatae Medical LLC, 390 Amwell Road, Building 5, Hillsborough, NJ 08844 USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell K. Spinnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology, 1555 Center Avenue, Fort Lee, NJ 07024 USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael M. Rothkopf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Mountain Medical Consultants, 1500 Pleasant Valley Way, Suite 201, West Orange, NJ 07052 USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Varunok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology Associates, 243 North Road, Suite 304, Poughkeepsie, NY 12601 USA</affiliation>
  </overall_official>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>M. Cristina Castelli, Ph.D.</name_title>
    <organization>Emisphere Technologies</organization>
  </responsible_party>
  <keyword>cobalamin</keyword>
  <keyword>B12</keyword>
  <keyword>homocysteine</keyword>
  <keyword>MMA</keyword>
  <keyword>holotranscobalamin</keyword>
  <keyword>Eligen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

